<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Broader</title>
	<atom:link href="http://www.tapanray.in/tag/broader/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Challenge of Holistic Value Creation With Pharma M&amp;A</title>
		<link>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-challenge-of-holistic-value-creation-with-pharma-ma</link>
		<comments>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/#comments</comments>
		<pubDate>Mon, 19 Aug 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[avant-garde]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cycle]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[possibilities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefining]]></category>
		<category><![CDATA[takeovers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[value-creation]]></category>
		<category><![CDATA[virtuous]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9675</guid>
		<description><![CDATA[Two mega deals, right at the dawn of 2019 gave a flying start to Merger &#38; Acquisition (M&#38;A) activities, in search of inorganic growth, by some large pharma companies. The two biggest ones are Bristol-Myers Squibb’s (BMS) USD 74 billion buyout of &#8230; <a href="http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India-like New Broader Compulsory Licensing Provisions in China Could Make the Global Pharma Players Edgy</title>
		<link>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy</link>
		<comments>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/#comments</comments>
		<pubDate>Mon, 18 Jun 2012 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Edgy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=79</guid>
		<description><![CDATA[Quite close on the heel of grant of Compulsory License (CL) to Bayer AG’s expensive Kidney and Liver cancer drug Sorafenib to the domestic Indian manufacturer Natco by the Indian Patent Office, as provided in the Indian Patent Law, China &#8230; <a href="http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
